• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SCYNEXIS Inc.

    6/20/24 8:01:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    S-8 1 form_s-8_-_june_20_2024_.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on June 20, 2024

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    SCYNEXIS, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    56-2181648

    (State or other jurisdiction of

    Incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    1 Evertrust Plaza, 13th Floor

    Jersey City, New Jersey 07302-6548

    (Address of principal executive offices) (Zip code)

    SCYNEXIS, Inc. 2024 Equity Incentive Plan

    (Full title of the plan)

    David Angulo, M.D.

    Chief Executive Officer

    SCYNEXIS, Inc.

    1 Evertrust Plaza, 13th Floor

    Jersey City, NJ 07302-6548

    (201) 884-5485

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

    Matthew B. Hemington

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    SCYNEXIS, Inc. (the “Registrant ”) is filing this Registration Statement on Form S-8 for the purpose of registering 6,150,000 shares of its Common Stock issuable to eligible persons under the SCYNEXIS, Inc. 2024 Equity Incentive Plan.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Securities and Exchange Commission (“SEC”) are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024;

    (b) The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the SEC on May 8, 2024;

    (c) The Registrant’s Current Report on Form 8-K filed with the SEC on January 2, 2024;

    (d) The description of the Registrant’s Common Stock that is contained in a registration statement on Form 8-A filed with the SEC on March 19, 2014 (File No. 001-36365), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 29, 2022; and

    (e) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s amended and restated certificate of incorporation permits indemnification of our directors, officers and other agents of the Registrant (and any other persons to which

    II-1


     

    applicable law permits the Registrant to provide indemnification)to the maximum extent permitted by the DGCL, and the Registrant’s amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit the Registrant to indemnify its other officers, employees and other agents, in each case to the maximum extent permitted by the DGCL.

    The Registrant has entered into indemnification agreements with its directors and officers, whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant.

    The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

     

     

    Incorporation by Reference

    Exhibit
    Number

    Description

    Form

    File No.

    Exhibit

    Filing Date

    4.1

    Amended and Restated Certificate of Incorporation

    8-K

    001-36365

    3.1

    5/12/2014

    4.2

    Certificate of Amendment of Amended and Restated Certificate of Incorporation

    10-Q

    001-36365

    3.2

    8/7/2019

    4.3

    Certificate of Amendment of Amended and Restated Certificate of Incorporation

    8-K

    001-36365

    3.1

    7/16/2020

    4.4

    Certificate of Amendment of Amended and Restated Certificate of Incorporation

    10-Q

    001-36365

    3.4

    11/9/2022

    4.5

    Amended and Restated Bylaws

    S-1

    333-194192

    3.4

    2/27/2014

    5.1*

    Opinion of Cooley LLP.

     

     

     

     

    23.1*

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

    23.2*

    Consent of Cooley LLP (reference is made to Exhibit 5.1).

     

     

     

     

    24.1*

    Power of Attorney (reference is made to the signature page hereto).

     

     

     

     

    99.1*

    SCYNEXIS, Inc. 2024 Equity Incentive Plan.

     

     

     

     

     


     

    99.2*

    Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the SCYNEXIS, Inc. 2024 Equity Incentive Plan.

     

     

     

     

    99.3*

    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the SCYNEXIS, Inc. 2024 Equity Incentive Plan.

     

     

     

     

    107*

    Filing Fee Table.

     

     

     

     

     

    * Filed herewith.

    Item 9. Undertakings.

    A. The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (4) That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     


     

    (i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

    (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

    (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

    (iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jersey City, State of New Jersey, on June 19, 2024.

     

     

     

    SCYNEXIS, Inc.

     

     

    By:

    /s/ David Angulo

     

    David Angulo, M.D.

     

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Angulo, M.D. and Scott Sukenick, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

    Name and Signature

    Title

    Date

     

     

     

     

     

    /s/ David Angulo, M.D.

    David Angulo, M.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    June 19, 2024

     

     

     

    /s/ Ivor Macleod

    Ivor Macleod

    Chief Financial Officer
    (Principal Financial and Accounting Officer)

            June 19, 2024

     

     

     

    /s/ Guy Macdonald

    Guy Macdonald

    Chairman of the Board of Directors

    June 19, 2024

     

     

     

    /s/ Armando Anido

    Armando Anido

    Director

    June 19, 2024

     

     

     

    /s/ Steven C. Gilman

    Steven C. Gilman, Ph.D.

    Director

    June 19, 2024

     

     

     

    /s/ Ann F. Hanham

    Ann F. Hanham, Ph.D.

    Director

         June 19, 2024

     

     

     

    /s/ David Hastings

    David Hastings

    Director

    June 19, 2024

     

     

     

     


     

    Name and Signature

    Title

    Date

     

    Brian Philippe Tinmouth

    Director

     

     


    Get the next $SCYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Macleod Ivor was granted 129,833 shares, increasing direct ownership by 48% to 398,529 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:03:14 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sukenick Scott was granted 129,833 shares, increasing direct ownership by 29% to 574,539 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:02:11 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Angulo Gonzalez David was granted 391,333 shares, increasing direct ownership by 46% to 1,244,431 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:01:08 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    9/16/24 8:00:27 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    1/8/26 8:19:28 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/25 2:27:47 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/12/25 1:09:48 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company's second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada. "We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance," said David Angulo, M.D., Presi

    1/28/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. "Receiving FDA's QIDP

    1/21/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SC

    12/22/25 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

    6/7/21 9:58:05 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

    4/12/21 12:54:40 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on SCYNEXIS with a new price target

    Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

    2/17/21 2:23:39 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    View All

    AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

    Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

    7/24/23 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

    Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

    5/17/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

    Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

    5/11/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Financials

    Live finance-specific insights

    View All

    GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

    Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

    3/30/23 7:05:00 AM ET
    $GSK
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

    11/9/22 7:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

    JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

    11/1/22 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/6/24 8:56:32 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    10/7/24 1:38:20 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care